Cannabis company Puration Inc. PURA announed Friday the sale of its cultivation business.
The Dallas-based company had previously spun-off the segment in a deal with Nouveau NOUV, in exchange for common stock. That deal has been canceled.
Instead, Puration has opted to merge the cultivation business with NCM Biotech, a subsidiary of Kali-Extracts KALY.
NCM Biotech specializes in the research and the development of treatments derived from its patented cannabis extraction process.
The common stock will be issued to Puration's shareholders in a dividend distribution at a ratio one-for-one.
In January, Puration and Kali-Extracts started negotiations about a prospective purchase of Kali-Extracts' CBD confection assets.
Two months later, Puration confirmed that the acquisition was underway.
Meanwhile, driven by estimations that the CBD pet products market in the U.S. could reach $1.16 billion over the next two years, Puration has made an offer to purchase an unspecified CBD pet products operation earlier this year.
Courtesy photo
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.